The 3 most recent market catalysts affecting $AKTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics has released encouraging preclinical data for AKTX-101, its novel TROP2-directed ADC, showing significant tumor inhibition in urothelial cancer models, including…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Akari Therapeutics has entered a research collaboration with Whitehawk Therapeutics to investigate combining Akari's PH1 spliceosome modulating payload platform with Whitehawk's to…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics has entered into a strategic research collaboration with Whitehawk Therapeutics. This collaboration focuses on preclinical studies to combine Akari's novel PH1 s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.